KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

AbCellera Biologics (ABCL) Return on Capital Employed (2021 - 2026)

AbCellera Biologics filings provide 6 years of Return on Capital Employed readings, the most recent being 16.5% for Q1 2026.

  • Quarterly Return on Capital Employed rose 876.0% to 16.5% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 16.5% through Mar 2026, up 876.0% year-over-year, with the annual reading at 16.77% for FY2025, 658.0% up from the prior year.
  • Return on Capital Employed hit 16.5% in Q1 2026 for AbCellera Biologics, up from 16.8% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 22.89% in Q3 2022 and bottomed at 25.26% in Q1 2025.
  • Average Return on Capital Employed over 5 years is 8.79%, with a median of 16.58% recorded in 2024.
  • The largest annual shift saw Return on Capital Employed crashed -3766bps in 2023 before it soared 876bps in 2026.
  • AbCellera Biologics' Return on Capital Employed stood at 15.16% in 2022, then tumbled by -213bps to 17.17% in 2023, then tumbled by -41bps to 24.21% in 2024, then soared by 31bps to 16.8% in 2025, then increased by 2bps to 16.5% in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Return on Capital Employed are 16.5% (Q1 2026), 16.8% (Q4 2025), and 19.94% (Q3 2025).